**Hot Take:** Milestone Pharma’s stock is a rollercoaster—FDA drama, a public offering, and a *66% plunge* from the CRL carnage. 📉 Yesterday’s RSI was screaming overbought (83!), but today’s nosedive to 41 says "panic mode." Volume? Explosive. The 9-day EMA just got sucker-punched below the 21-day. News-wise, they’re hustling (FDA resubmission, conferences), but dilution fears loom. Chart’s a mess—no clear pattern, just whiplash. **Verdict:** SELL until the dust settles. This ain’t for the faint-hearted. #BiotechBombshell

FDA drama has this biotech on a wild ride! 📈 The recent CRL rejection crushed it, but now they're bouncing hard on regulatory progress and conference buzz. RSI hovering near 70 shows buyers are back, and that 9-period WMA is pulling ahead. Volume spikes confirm the conviction. This feels like a speculative BUY for the brave – the chart's building a base for the next catalyst.

#BiotechBets

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Milestone Pharmaceuticals Inc. MIST: 1.82 USD

Bullish views

Bearish views